Remission of Severe Eyelid Dermatitis With a Topical Janus Kinase Inhibitor

被引：2
|
作者：
Peterson, Danielle [1 ]
King, Brett [1 ]
机构：
[1] Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA
来源：
DERMATITIS | 2021年 / 32卷 / 1S期
关键词：
ATOPIC-DERMATITIS;
D O I：
10.1097/DER.0000000000000783
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E98 / E99
页数：2
相关论文
共 50 条
  • [21] Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: A case series
    Ju, Teresa
    Labib, Angelina
    Vander Does, Ashley
    Yosipovitch, Gil
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) : 400 - 403
  • [22] Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
    Punwani, N.
    Burn, T.
    Scherle, P.
    Flores, R.
    Shi, J.
    Collier, P.
    Hertel, D.
    Haley, P.
    Lo, Y.
    Waeltz, P.
    Rodgers, J.
    Shepard, S.
    Vaddi, K.
    Yeleswaram, S.
    Levy, R.
    Williams, W.
    Gottlieb, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (04) : 989 - 997
  • [23] Cerdulatinib (DMVT-502), a novel, topical dual Janus kinase/spleen tyrosine kinase inhibitor, improves the cellular and molecular cutaneous signature in patients with atopic dermatitis
    Piscitelli, S.
    Lee, J.
    McHale, K.
    Collins, J.
    Gillmor, D.
    Tabolt, G.
    Li, R.
    Pavel, A. B.
    Tallman, A. M.
    Guttman-Yassky, E.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 44 - 45
  • [24] Safety of Oral Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Narla, Shanthi
    Silverberg, Jonathan I.
    DERMATITIS, 2023, : 366 - 386
  • [25] Predictors of maintenance of response in patients with moderate to severe atopic dermatitis after oral Janus kinase 1 selective inhibitor abrocitinib interruption
    Gooderham, Melinda J.
    Girolomoni, Giampiero
    Moore, Julian O'Neil
    Silverberg, Jonathan I.
    Curto, Madelyn
    Zhang, Weidong
    DiBonaventura, Marco
    Valdez, Hernan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB64 - AB64
  • [26] Biologic and Janus kinase inhibitor therapy outcomes for severe psoriasis in trisomy 21
    O'Connor, Cathal
    Byrne, Berbie
    Roche, Darren
    O'Connell, Garret
    O'Connell, Michael
    Murphy, Michelle
    Bourke, John
    Lynch, Maeve
    Bennett, Mary
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [27] Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
    Powers, Camille M.
    Verma, Hannah
    Orloff, Jeremy
    Piontkowski, Austin J.
    Tiersten, Amy
    Lamb, Angela
    Gulati, Nicholas
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [28] Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
    Abduelmula, Abrahim
    Mufti, Asfandyar
    Chong, Derrick HY.
    Sood, Siddhartha
    Sachdeva, Muskaan
    Yeung, Jensen
    JAAD INTERNATIONAL, 2022, 9 : 156 - 158
  • [29] Janus kinase inhibitors for the therapy of atopic dermatitis
    Traidl, S.
    Freimooser, S.
    Werfel, T.
    ALLERGOLOGIE, 2021, 44 (09) : 710 - 723
  • [30] Oclacitinib, a novel Janus kinase inhibitor for the treatment of atopic dermatitis and other case of pruritus in dogs
    Akos, Jerzsele
    Dora, Kovacs
    Zoltan, Somogyi
    MAGYAR ALLATORVOSOK LAPJA, 2017, 139 (09) : 545 - 552
12345